Company intelligence / Profile preview
Coherent Biopharma
Suzhou, Jiangsu, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~110
- Development stage
- Phase 2
01
Overview
CBP-1008 has demonstrated impressive efficacy and safety profile with over 350 patients treated. CBP-1018 has shown superior profile in Phase I/II studies with 120 patients treated, with 8.5 months of median rPFS for all mCRPC patients. CBP-1019 received Fast Track Designation from FDA for treatment of recurrent endometrial cancer.
- Therapeutic areas
- Oncology
- Modalities
- Bi-targeting XDC drugsPeptide Drug Conjugates (PDC)PROTACsRadiopharmaceutical Therapy (RPT)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
WuXi STA
Beyond the preview
Go deeper on Coherent Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coherent Biopharma.